← Back to Search

Phosphodiesterase inhibitor

Ibudilast for COVID-19

Phase 2
Waitlist Available
Research Sponsored by MediciNova
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 7, 14, and 28

Summary

This trial is testing ibudilast in hospitalized COVID-19 patients who are at risk of severe lung problems. The drug aims to reduce inflammation and calm the immune response to prevent severe lung issues. Patients will receive the drug for a short period and be monitored for several weeks.

Eligible Conditions
  • Viral Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 7, 14, and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 7, 14, and 28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants Free From Respiratory Failure at Day 7
Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7
Secondary study objectives
All-cause Mortality
Number of Participants Discharged From Hospital at Days 7, 14, and 28
Number of Participants Receiving Mechanical Ventilation or Intubation

Side effects data

From 2017 Phase 2 trial • 125 Patients • NCT01860807
50%
Headache
17%
Nausea
16%
Insomnia
13%
Diarrhea
2%
Suicide Attempt
2%
Convulsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ibudilast
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active Treatment GroupExperimental Treatment1 Intervention
Group II: Placebo Treatment GroupPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibudilast
2016
Completed Phase 2
~410

Find a Location

Who is running the clinical trial?

MediciNovaLead Sponsor
19 Previous Clinical Trials
1,480 Total Patients Enrolled
Kazuko Matsuda, MD PhD MPHStudy ChairMedicinova Inc
4 Previous Clinical Trials
339 Total Patients Enrolled

Media Library

Ibudilast (Phosphodiesterase inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04429555 — Phase 2
Viral Pneumonia Research Study Groups: Active Treatment Group, Placebo Treatment Group
Viral Pneumonia Clinical Trial 2023: Ibudilast Highlights & Side Effects. Trial Name: NCT04429555 — Phase 2
Ibudilast (Phosphodiesterase inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04429555 — Phase 2
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top